|
Acamprosate Treatment: Mechanisms of Action Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Acamprosate Treatment: Mechanisms of Action conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Acamprosate Treatment: Mechanisms of Action Clinical research trials and Acamprosate Treatment: Mechanisms of Action health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Acamprosate Treatment: Mechanisms of Action. Acamprosate Treatment: Mechanisms of Action Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Acamprosate Treatment: Mechanisms of Action clinical trial. Participants oftentimes recieve the most expert healthcare available for their Acamprosate Treatment: Mechanisms of Action condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Acamprosate Treatment: Mechanisms of Action  Acamprosate Treatment: Mechanisms of Action
Acamprosate Treatment: Mechanisms of Action
For Condition: Alcoholism
Status: Completed
Sponsor(s): National Institute on Alcohol Abuse and Alcoholism (NIAAA) ,
Synopsis: This study will examine whether pretreatment with two doses of acamprosate for seven days prior to abstinence lessens the intensity of acute withdrawal from alcohol compared with a placebo. Subjects will be randomly assigned to receive either one of two doses of acramprosate or placebo for seven days. This will be followed by a four- day inpatient period when withdrawal will be monitored. Additional drinking information will be obtained at a three month followup interview.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 21 Years/55 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Meets criteria for alcohol abuse or dependence. - Able to read English at 6th grade level or higher and to complete study evaluations. - Average weekly alcohol consumption of standard drinks of at least 25 drinks for men and 20 drinks for women. - No more than 3 days abstinence/week. Exclusion Criteria: - Current abuse or dependence on other substances, other than nicotine and marijuana. - Positive test results for opiates, cocaine, benzodiazepines and barbiturates. - Regular use of psychoactive drugs including anxiolytics and antidepressants. - Psychiatrically disabled. - Hepatocellular disease or a history of cirrhosis. - Medical conditions that would prevent the consumption of alcohol, increase the risk of complicated alcohol withdrawal, or prevent the use of acamprosate such as a history of neurological trauma or disease, seizures, delirium, or hallucinations, hepatic, cardiovascular, metabolic, endocrine, gastrointestinal, or kidney disease. - Individuals who have had any significant physical illnesses during the two weeks prior to receiving study medication or during the medication treatment period prior to the withdrawal study. - Medically detoxified from alcohol more than once within the past five years. - Alcohol withdrawal symptoms requiring management with benzodiazepines. - Females who are pregnant, nursing or not using a reliable method of birth control. - Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past six months. - Individuals who report disliking spirits and have taken investigational drug or naltrexone within 4 weeks immediately preceding admission to study. - Individuals who report any daily drug use during the thirty days prior to randomization for the following: anxiolytics, beta blockers, central nervous system stimulants, hypnotics, non-therapeutic doses of neuroleptics and antidepressants, drugs with psychotropic activity or drugs which cause excessive sedation. - Subjects who have donated blood within the past six weeks.
Total Enrollment: 120
Location and Contact Information:
Substance Abuse Treatment Unit, University of Connecticut
New Haven, Connecticut, 06511
United States
Additional Information:
Study ID Numbers: NIAAAOMA03510;
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004552
Other Alcoholism Studies:
1. Tobacco Dependence in Alcoholism Treatment (nicotine patch/naltrexone)
2. Drug Therapy for Alcohol Detoxification
3. Naltrexone for Relapse Prevention
4. Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
5. Smoking Cessation in Alcoholism Treatment
Related Studies:
Other Alcoholism Clinical Trials
Other Connecticut Clinical Trials
Other New Haven Clinical Trials
Acamprosate Treatment: Mechanisms of Action
|
|
|
|
|
|
|
|
